AQST logo

Aquestive Therapeutics (AQST)

Profile

Full Name

Aquestive Therapeutics, Inc.

Ticker Symbol

AQST

Exchange

NASDAQ

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

IPO

July 25, 2018

Indexes

Not included

Website

http://www.aquestive.com

Employees

142

Key Details

Price

$2.57(+1.98%)

Market cap

$254.10M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$57.56M(+13.80% YoY)

Annual EPS

-$0.51(-292.31% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$2.57
AQST price is $2.57

30-Day Relative Volume

0.57
AQST 30-day relative volume is 0.57

Price Performance

Price Most recent change

+1.98%
AQST price was up +1.98% on Apr 15, 2025

Price YTD change

-27.81%
AQST price is down -27.81% since January 1st

Price 1-year change

-34.77%
AQST price is down -34.77% year-on-year

Price 3-year change

+22.97%
AQST price is up +22.97% over the past 3 years

Price Range

Price All-time high

$20.70
AQST price is currently -87.58% below its historical high of $20.70

Price 3-year low

$0.62
AQST price is currently +315.86% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$254.10M
AQST market capitalization is $254.10 million

Market cap 3-year change

+193.29%
AQST market capitalization is up +193.29% over the past 3 years

Market cap All-time high

$516.98M
AQST market capitalization is currently -50.85% below its historical high of $516.98 million

Market cap sector rank

61.1%
AQST market capitalization is higher than 61.1% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+9.28%
AQST shares outstanding is up +9.28% year-on-year

Shares Outstanding 3-Year Change

+138.51%
AQST shares outstanding is up +138.51% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.45
AQST beta is 1.45

200-day SMA

$3.79
AQST price is currently -32.14% below its 200-day simple moving average

50-day SMA

$2.89
AQST price is currently -10.95% below its 50-day simple moving average

RSI

43.47
AQST 14-day relative strength index is 43.47

Volume

0.57
AQST 30-day relative volume is 0.57

ATR

$0.21
AQST average true range is $0.21

10-day Historical Volatility

95.39%
AQST 10-day historical volatility is 95.39%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$57.56M
AQST annual revenue is $57.56 million

Revenue Analysts estimate

$49.58M
AQST annual revenue is currently +16.10% higher than the consensus analysts' forecast

Revenue 1-year change

+13.8%
AQST annual revenue is up +13.8% year-on-year

Revenue Sector rank

49.05%
AQST annual revenue is higher than 49.05% of companies in Healthcare sector

EPS

EPS

-$0.51
AQST annual earnings per share is -$0.51

EPS Analysts estimate

-$0.64
AQST annual earnings per share is currently -20.31% lower than the consensus analysts' forecast

EPS 1-year change

-292.31%
AQST annual earnings per share is down -292.31% year-on-year

EPS Sector rank

68.52%
AQST annual earnings per share is higher than 68.52% of companies in Healthcare sector

Profit

Gross profit

$39.69M
AQST annual gross profit is $39.69 million

Gross margin

68.95%
AQST annual gross profit margin is 68.95%

Operating profit

-$30.77M
AQST annual operating income is -$30.77 million

Operating margin

-53.46%
AQST annual operating profit margin is -53.46%

Net income

-$44.14M
AQST annual net profit is -$44.14 million

Net margin

-76.68%
AQST annual net profit margin is -76.68%

Expenses

Total expenses

$88.33M
AQST annual total expenses is $88.33 million

Operating expenses

$70.46M
AQST annual total operating expenses is $70.46 million

Cost of goods sold

$17.87M
AQST annual cost of goods sold is $17.87 million

Selling, general & administrative expenses

$50.18M
AQST annual SGA is $50.18 million

Depreciation and amortization

$718.00K
AQST annual depreciation & amortization is $718.00 thousand

Interest expense

$16.82M
AQST annual interest expense is $16.82 million

Income tax

-$14.00K
AQST annual income tax is -$14.00 thousand

EBIT & EBITDA

EBIT

-$27.33M
AQST annual earnings before interest & taxes is -$27.33 million

EBITDA

-$26.62M
AQST annual EBITDA is -$26.62 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$101.42M
AQST annual total assets is $101.42 million

Non current assets

$13.20M
AQST annual long term assets is $13.20 million

Current assets

$88.22M
AQST annual total current assets is $88.22 million

Cash and cash equivalents

$71.55M
AQST annual cash & cash equivalents is $71.55 million

Accounts receivable

$4.92M
AQST annual accounts receivable is $4.92 million

Inventory

$6.04M
AQST annual inventory is $6.04 million

Liabilities

Total liabilities

$161.58M
AQST annual total liabilities is $161.58 million

Long term liabilities

$142.72M
AQST annual total long term liabilities is $142.72 million

Current liabilities

$18.86M
AQST annual total current liabilities is $18.86 million

Accounts payable

$10.29M
AQST annual accounts payable is $10.29 million

Debt

Total debt

$38.00M
AQST annual total debt is $38.00 million

Total debt 1-year change

+14.06%
AQST annual total debt is up +14.06% year-on-year

Long term debt

$37.47M
AQST annual long term debt is $37.47 million

Short term debt

$536.00K
AQST annual short term debt is $536.00 thousand

Equity & Capital

Shareholders equity

-$60.16M
AQST annual stockholders equity is -$60.16 million

Book value

-$60.16M
AQST annual book value is -$60.16 million

Retained earnings

-$363.21M
AQST annual retained earnings is -$363.21 million

Working capital

$69.36M
AQST annual working capital is $69.36 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$35.76M
AQST annual cash flow from operations is -$35.76 million

Cash from operations 1-year change

-460.49%
AQST annual cash flow from operations is down -460.49% year-on-year

Cash from investing

-$159.00K
AQST annual cash flow from investing activities is -$159.00 thousand

Cash from investing 1-year change

+84.02%
AQST annual cash flow from investing activities is up +84.02% year-on-year

Cash from financing

$83.59M
AQST annual cash flow from financing activities is $83.59 million

Cash from financing 1-year change

+2003.47%
AQST annual cash flow from financing activities is up +2003.47% year-on-year

CAPEX

CAPEX

$159.00K
AQST annual capital expenditures is $159.00 thousand

CAPEX 1-year change

-84.02%
AQST annual capital expenditures is down -84.02% year-on-year

Free Cash Flow

Free cash flow

-$35.92M
AQST annual free cash flow is -$35.92 million

Free cash flow 1-year change

-387.02%
AQST annual free cash flow is down -387.02% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

68.95%
AQST annual gross profit margin is 68.95%

Operating margin

-53.46%
AQST annual operating profit margin is -53.46%

Net margin

-76.68%
AQST annual net profit margin is -76.68%

ROA & ROE

ROA

-55.57%
AQST annual return on assets is -55.57%

ROE

73.37%
AQST annual return on equity is 73.37%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
AQST price to earnings ratio value is unknown

PE ratio Sector rank

-
AQST price to earnings ratio is unknown

PB Ratio

PB ratio

-4.22
AQST price to book ratio is -4.22

PB ratio Sector rank

4.69%
AQST price to book ratio is higher than 4.69% of companies in Healthcare sector

PS Ratio

PS ratio

4.41
AQST price to sales ratio is 4.41

PS ratio Sector rank

63.59%
AQST price to sales ratio is higher than 63.59% of companies in Healthcare sector

Enterprise value

Enterprise value

$220.56M
AQST enterprise value is $220.56 million

Enterprise value Sector rank

59.88%
AQST enterprise value is higher than 59.88% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-8.29
AQST EV/EBITDA is -8.29

EV/EBITDA Sector rank

12.53%
AQST EV/EBITDA is higher than 12.53% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

4.68
AQST annual current ratio is 4.68

Quick ratio

4.36
AQST annual quick ratio is 4.36

Leverage

Debt to equity

-0.54
AQST annual debt to equity ratio is -0.54

Interest coverage ratio

-1.63
AQST annual interest coverage ratio is -1.63

Risk & Stability

Piotroski F-Score

2
AQST piotroski f-score is 2

Altman Z-Score

-3.57
AQST altman z-score is -3.57

Analyst ratings

Recent major analysts updates

Apr 2, 25 HC Wainwright & Co.
Buy
Mar 10, 25 HC Wainwright & Co.
Buy
Mar 7, 25 Lake Street
Buy
Dec 20, 24 HC Wainwright & Co.
Buy
Dec 17, 24 Cantor Fitzgerald
Overweight
Nov 11, 24 HC Wainwright & Co.
Buy
Nov 6, 24 HC Wainwright & Co.
Buy
Oct 25, 24 Leerink Partners
Outperform
Oct 25, 24 HC Wainwright & Co.
Buy
Oct 8, 24 JMP Securities
Market Outperform

Institutional Ownership

Similar stocks

VNDA logo
Vanda Pharmaceuticals (VNDA)
EBS logo
Emergent BioSolutions (EBS)
ZIMV logo
ZimVie (ZIMV)
NRC logo
National Research (NRC)
XOMA logo
XOMA (XOMA)
MRVI logo
Maravai LifeSciences Holdings (MRVI)
HCAT logo
Health Catalyst (HCAT)
STIM logo
Neuronetics (STIM)
TSVT logo
2seventy bio (TSVT)
  • What is the ticker symbol for Aquestive Therapeutics?
  • Does Aquestive Therapeutics pay dividends?
  • What sector is Aquestive Therapeutics in?
  • What industry is Aquestive Therapeutics in?
  • What country is Aquestive Therapeutics based in?
  • When did Aquestive Therapeutics go public?
  • Is Aquestive Therapeutics in the S&P 500?
  • Is Aquestive Therapeutics in the NASDAQ 100?
  • Is Aquestive Therapeutics in the Dow Jones?
  • When was Aquestive Therapeutics's last earnings report?
  • When does Aquestive Therapeutics report earnings?
  • Should I buy Aquestive Therapeutics stock now?

What is the ticker symbol for Aquestive Therapeutics?

The ticker symbol for Aquestive Therapeutics is NASDAQ:AQST

Does Aquestive Therapeutics pay dividends?

No, Aquestive Therapeutics does not pay dividends

What sector is Aquestive Therapeutics in?

Aquestive Therapeutics is in the Healthcare sector

What industry is Aquestive Therapeutics in?

Aquestive Therapeutics is in the Drug Manufacturers - Specialty & Generic industry

What country is Aquestive Therapeutics based in?

Aquestive Therapeutics is headquartered in United States

When did Aquestive Therapeutics go public?

Aquestive Therapeutics's initial public offering (IPO) was on July 25, 2018

Is Aquestive Therapeutics in the S&P 500?

No, Aquestive Therapeutics is not included in the S&P 500 index

Is Aquestive Therapeutics in the NASDAQ 100?

No, Aquestive Therapeutics is not included in the NASDAQ 100 index

Is Aquestive Therapeutics in the Dow Jones?

No, Aquestive Therapeutics is not included in the Dow Jones index

When was Aquestive Therapeutics's last earnings report?

Aquestive Therapeutics's most recent earnings report was on Mar 5, 2025

When does Aquestive Therapeutics report earnings?

The next expected earnings date for Aquestive Therapeutics is May 7, 2025

Should I buy Aquestive Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page